Bolotina, L. V. (2020). Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma. IP Habib O.N.
Chicago Style (17th ed.) CitationBolotina, L. V. Lenvatinib as the Key Component of First-line Therapy for Patients with Unresectable Hepatocellular Carcinoma. IP Habib O.N, 2020.
MLA (8th ed.) CitationBolotina, L. V. Lenvatinib as the Key Component of First-line Therapy for Patients with Unresectable Hepatocellular Carcinoma. IP Habib O.N, 2020.
Warning: These citations may not always be 100% accurate.